Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
3.
Health Aff (Millwood) ; 35(5): 798-804, 2016 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-27140985

RESUMEN

Early evidence suggests that provisions of the Food and Drug Administration Safety and Innovation Act of 2012 are associated with reductions in the total number of new national drug shortages. However, drugs frequently used in acute unscheduled care such as the care delivered in emergency departments may be increasingly affected by shortages. Our estimates, based on reported national drug shortages from 2001 to 2014 collected by the University of Utah's Drug Information Service, show that although the number of new annual shortages has decreased since the act's passage, half of all drug shortages in the study period involved acute care drugs. Shortages affecting acute care drugs became increasingly frequent and prolonged compared with non-acute care drugs (median duration of 242 versus 173 days, respectively). These results suggest that the drug supply for many acutely and critically ill patients in the United States remains vulnerable despite federal efforts.


Asunto(s)
Servicio de Urgencia en Hospital/organización & administración , Gobierno Federal , Medicamentos bajo Prescripción/provisión & distribución , Enfermedad Crítica/terapia , Industria Farmacéutica/organización & administración , Sustitución de Medicamentos/métodos , Humanos , Factores de Tiempo , Estados Unidos , United States Food and Drug Administration
4.
Am J Cardiol ; 116(12): 1827-32, 2015 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-26541907

RESUMEN

This prospective study assessed whether gender differences in health insurance help explain gender differences in delay in seeking care for patients in the US, with acute myocardial infarction (AMI). We also assessed gender differences in such prehospital delay for AMI in Spain, a country with universal insurance. We used data from 2,951 US and 496 Spanish patients aged 18 to 55 years with AMI. US patients were grouped by insurance status: adequately insured, underinsured, or uninsured. For each country, we assessed the association between gender and prehospital delay (symptom onset to hospital arrival). For the US cohort, we modeled the relation between insurance groups and delay of >12 hours. US women were less likely than men to be uninsured but more likely to be underinsured, and a larger proportion of women than men experienced delays of >12 hours (38% vs 29%). We found no association between insurance status and delays of >12 hours in men or women. Only 17.3% of Spanish patients had delays of >12 hours, and there were no significant gender differences. In conclusion, women were more likely than men to delay, although it was not explained by differences in insurance status. The lack of gender differences in prehospital delays in Spain suggests that these differences may vary by health care system and culture.


Asunto(s)
Atención a la Salud/economía , Servicios Médicos de Urgencia/economía , Seguro de Salud/estadística & datos numéricos , Infarto del Miocardio/economía , Admisión del Paciente/tendencias , Adolescente , Adulto , Femenino , Humanos , Masculino , Pacientes no Asegurados/estadística & datos numéricos , Persona de Mediana Edad , Infarto del Miocardio/mortalidad , Infarto del Miocardio/terapia , Admisión del Paciente/economía , Estudios Prospectivos , España/epidemiología , Tasa de Supervivencia/tendencias , Factores de Tiempo , Estados Unidos/epidemiología , Adulto Joven
5.
PLoS One ; 9(10): e109583, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25337815

RESUMEN

BACKGROUND: Google Trends is a novel, freely accessible tool that allows users to interact with Internet search data, which may provide deep insights into population behavior and health-related phenomena. However, there is limited knowledge about its potential uses and limitations. We therefore systematically reviewed health care literature using Google Trends to classify articles by topic and study aim; evaluate the methodology and validation of the tool; and address limitations for its use in research. METHODS AND FINDINGS: PRISMA guidelines were followed. Two independent reviewers systematically identified studies utilizing Google Trends for health care research from MEDLINE and PubMed. Seventy studies met our inclusion criteria. Google Trends publications increased seven-fold from 2009 to 2013. Studies were classified into four topic domains: infectious disease (27% of articles), mental health and substance use (24%), other non-communicable diseases (16%), and general population behavior (33%). By use, 27% of articles utilized Google Trends for casual inference, 39% for description, and 34% for surveillance. Among surveillance studies, 92% were validated against a reference standard data source, and 80% of studies using correlation had a correlation statistic ≥0.70. Overall, 67% of articles provided a rationale for their search input. However, only 7% of articles were reproducible based on complete documentation of search strategy. We present a checklist to facilitate appropriate methodological documentation for future studies. A limitation of the study is the challenge of classifying heterogeneous studies utilizing a novel data source. CONCLUSION: Google Trends is being used to study health phenomena in a variety of topic domains in myriad ways. However, poor documentation of methods precludes the reproducibility of the findings. Such documentation would enable other researchers to determine the consistency of results provided by Google Trends for a well-specified query over time. Furthermore, greater transparency can improve its reliability as a research tool.


Asunto(s)
Investigación sobre Servicios de Salud , Internet , Motor de Búsqueda , Humanos , MEDLINE
9.
Circulation ; 127(8): 923-9, 2013 Feb 26.
Artículo en Inglés | MEDLINE | ID: mdl-23355624

RESUMEN

BACKGROUND: Despite increasing attention on reducing relatively costly hospital practices while maintaining the quality of care, few studies have examined how hospitals use the intensive care unit (ICU), a high-cost setting, for patients admitted with heart failure (HF). We characterized hospital patterns of ICU admission for patients with HF and determined their association with the use of ICU-level therapies and patient outcomes. METHODS AND RESULTS: We identified 166 224 HF discharges from 341 hospitals in the 2009-2010 Premier Perspective database. We excluded hospitals with <25 HF admissions, patients <18 years old, and transfers. We defined ICU as including medical ICU, coronary ICU, and surgical ICU. We calculated the percent of patients admitted directly to an ICU. We compared hospitals in the top quartile (high ICU admission) with the remaining quartiles. The median percentage of ICU admission was 10% (interquartile range, 6%-16%; range, 0%-88%). In top-quartile hospitals, treatments requiring an ICU were used less often; the percentage of ICU days receiving mechanical ventilation was 6% for the top quartile versus 15% for the others; noninvasive positive pressure ventilation, 8% versus 19%; vasopressors and/or inotropes, 9% versus 16%; vasodilators, 6% versus 12%; and any of these interventions, 26% versus 51%. Overall HF in-hospital risk-standardized mortality was similar (3.4% versus 3.5%; P=0.2). CONCLUSIONS: ICU admission rates for HF varied markedly across hospitals and lacked association with in-hospital risk-standardized mortality. Greater ICU use correlated with fewer patients receiving ICU interventions. Judicious ICU use could reduce resource consumption without diminishing patient outcomes.


Asunto(s)
Bases de Datos Factuales/tendencias , Insuficiencia Cardíaca/terapia , Hospitales/tendencias , Unidades de Cuidados Intensivos/tendencias , Admisión del Paciente/tendencias , Estudios de Cohortes , Estudios Transversales , Femenino , Insuficiencia Cardíaca/economía , Insuficiencia Cardíaca/mortalidad , Mortalidad Hospitalaria/tendencias , Humanos , Unidades de Cuidados Intensivos/economía , Masculino , Admisión del Paciente/economía , Estados Unidos/epidemiología
10.
Circ Cardiovasc Qual Outcomes ; 5(3): 308-13, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22576844

RESUMEN

BACKGROUND: The intensive practice style of hospitals with high procedure rates may result in higher costs of care for medically managed patients. We sought to determine how costs for patients with heart failure (HF) not receiving procedures compare between hospital groups defined by their overall use of procedures. METHODS AND RESULTS: We identified all 2009 to 2010 adult HF hospitalizations in hospitals capable of performing invasive procedures that had at least 25 HF hospitalizations in the Perspective database from Premier, Inc. We divided hospitals into 2 groups by the proportion of patients with HF receiving invasive percutaneous or surgical procedures: low (>0%-10%) and high (≥ 10%). The standard costs of hospitalizations at each hospital were risk adjusted using patient demographics and comorbidities. We used the Wilcoxon rank sum test to assess cost, length of stay, and mortality outcome differences between the 2 groups. Median risk-standardized costs among low-procedural HF hospitalizations were $5259 (interquartile range, $4683-$6814) versus $6965 (interquartile range, $5981-$8235) for hospitals with high procedure use (P<0.001). Median length of stay was 4 days for both groups. Risk-standardized mortality rates were 5.4% (low procedure) and 5.0% (high procedure) (P=0.009). We did not identify any single service area that explained the difference in costs between hospital groups, but these hospitals had higher costs for most service areas. CONCLUSION: Among patients who do not receive invasive procedures, the cost of HF hospitalization is higher in more procedure-intense hospitals compared with hospitals that perform fewer procedures.


Asunto(s)
Insuficiencia Cardíaca/economía , Insuficiencia Cardíaca/terapia , Costos de Hospital , Hospitalización/economía , Evaluación de Procesos y Resultados en Atención de Salud/economía , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Costos y Análisis de Costo , Estudios Transversales , Femenino , Insuficiencia Cardíaca/mortalidad , Capacidad de Camas en Hospitales/economía , Mortalidad Hospitalaria , Hospitales Rurales/economía , Hospitales de Enseñanza/economía , Hospitales Urbanos/economía , Humanos , Tiempo de Internación/economía , Modelos Lineales , Masculino , Persona de Mediana Edad , Modelos Económicos , Características de la Residencia , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo , Resultado del Tratamiento , Estados Unidos , Adulto Joven
11.
Dev Neurosci ; 31(6): 497-510, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19738365

RESUMEN

Down syndrome (DS) is a developmental disorder whose mental impairment is due to defective cortical development. Human neural progenitor cells (hNPCs) derived from fetal DS cortex initially produce normal numbers of neurons, but generate fewer neurons with time in culture, similar to the pattern of neurogenesis that occurs in DS in vivo. Microarray analysis of DS hNPCs at this critical time reveals gene changes indicative of defects in interneuron progenitor development. In addition, dysregulated expression of many genes involved in neural progenitor cell biology points to changes in the progenitor population and subsequent reduction in interneuron neurogenesis. Delineation of a critical period in interneuron development in DS provides a foundation for investigation of the basis of reduced neurogenesis in DS and defines a time when these progenitor cells may be amenable to therapeutic treatment.


Asunto(s)
Corteza Cerebral/fisiopatología , Síndrome de Down/fisiopatología , Expresión Génica/genética , Interneuronas/fisiología , Neurogénesis/fisiología , Recuento de Células , Muerte Celular , Células Cultivadas , Corteza Cerebral/metabolismo , Síndrome de Down/genética , Síndrome de Down/metabolismo , Feto , Técnica del Anticuerpo Fluorescente , Perfilación de la Expresión Génica , Ácido Glutámico/metabolismo , Humanos , Interneuronas/metabolismo , Células Madre Multipotentes , Neurogénesis/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factores de Tiempo , Proteína 1 de Transporte Vesicular de Glutamato/metabolismo , Proteínas del Transporte Vesicular de Aminoácidos Inhibidores/metabolismo , Ácido gamma-Aminobutírico/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA